|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0030705,
umls-concept:C0098361,
umls-concept:C0201734,
umls-concept:C0205390,
umls-concept:C0280100,
umls-concept:C0332174,
umls-concept:C0442027,
umls-concept:C1442162,
umls-concept:C1550718
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2000-12-26
|
|
pubmed:abstractText |
Fluorouracil (5-FU) given as a weekly, high-dose 24-hour infusion is active and tolerable. We evaluated an oral regimen of eniluracil (which inactivates dihydropyrimidine dehydrogenase [DPD]), 5-FU, and leucovorin to simulate this schedule.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BiD QDQ,
pubmed-author:DonavanSS,
pubmed-author:GremJ LJL,
pubmed-author:GrollmanFF,
pubmed-author:HamiltonJ MJM,
pubmed-author:HaroldNN,
pubmed-author:KeithBB,
pubmed-author:MonahanB PBP,
pubmed-author:MorrisonGG,
pubmed-author:QuinnM GMG,
pubmed-author:ShapiroJJ,
pubmed-author:TakimotoC HCH,
pubmed-author:ZentkoSS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3952-63
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11099325-Administration, Oral,
pubmed-meshheading:11099325-Adult,
pubmed-meshheading:11099325-Aged,
pubmed-meshheading:11099325-Antimetabolites, Antineoplastic,
pubmed-meshheading:11099325-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11099325-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:11099325-Drug Administration Schedule,
pubmed-meshheading:11099325-Enzyme Inhibitors,
pubmed-meshheading:11099325-Female,
pubmed-meshheading:11099325-Fluorouracil,
pubmed-meshheading:11099325-Humans,
pubmed-meshheading:11099325-Infusions, Intravenous,
pubmed-meshheading:11099325-Leucovorin,
pubmed-meshheading:11099325-Male,
pubmed-meshheading:11099325-Middle Aged,
pubmed-meshheading:11099325-Neoplasms,
pubmed-meshheading:11099325-Oxidoreductases,
pubmed-meshheading:11099325-Uracil
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
|
|
pubmed:affiliation |
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889, USA. jgrem@helix.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase I
|
